Coiled-coil domain containing 85 B (CCDC85B) is involved in diverse biological processes; however, its expression patterns and functions in human cancers are yet unknown. The present study demonstrated that the expression of CCDC85B in the cytoplasm of the non-small cell lung cancer (NSCLC) tumor cells was significantly higher compared to adjacent normal lung tissues (P < 0.05). Furthermore, CCDC85B expression correlated with advanced TNM stage (P = 0.004) and positive regional lymph node metastasis (P = 0.009) of NSCLC. In addition, in A549 and H1299 lung cancer cell lines, the overexpression of CCDC85B promoted cell proliferation and invasion, while siRNA-mediated CCDC85B knockdown exhibited opposite effects.
| INTRODUCTION
Coiled-coil domain containing (CCDC) family members contain coiled-coil domains, and the proteins containing this domain function in several physiological processes, such as the regulation of signal transduction, gene expression, cell division, and cell motility. 1, 2 Accumulating evidence indicates that CCDC family members have diverse roles in tumorigenesis and tumor progression. [3] [4] [5] [6] CCDC85B is a 202-amino acid protein with two internal coiledcoil domains and no other recognizable domains. This protein is associated with the hepatitis delta antigen, and this interaction affects viral genomic replication; thus, it is also known as delta-interacting protein A (DIPA). 7 CCDC85B has been shown to participate in regulating adipogenesis and adipocyte differentiation. 8, 9 Du et al 10 have found that CCDC85B interacts with p78/MCRS/MSP58 and has a role in the regulation of gene expression and cell proliferation.
Furthermore, CCDC85B is also involved in Wnt signaling pathway by inhibiting the interaction of β-catenin with the T-cell factor 4 in the nucleus. 11 These results indicated that CCDC85B might function in tumorigenesis and tumor progression. However, the expression patterns and functions of CCDC85B in human cancers remain unclear.
Abbreviations: CCDC85B, coiled-coil domain containing 85 B; NSCLC, non-small cell lung cancer; WB, Western blot; HBE, human normal bronchial epithelial; PBS, phosphatebuffered saline.
In this study, we explored the expression of CCDC85B and the correlation with clinicopathological features of NSCLC. We also investigated the effects of CCDC85B on lung cancer cell proliferation and invasion. We further investigated the underlying mechanisms of its biological effects in NSCLC cells. The obtained results suggested that CCDC85B may be a target in the treatment of NSCLC.
| MATERIALS AND METHODS

| Patients and specimens
All human specimens were derived from patients who provided informed consent. The study was approved by the ethics committee of China Medical University. In the study, all the specimens including NSCLC tissue (n = 159) and adjacent normal lung tissue (n = 38) (at a distance of >5 cm from the edge of the primary tumor) were obtained (squamous cell carcinoma: T1, T3, T5, T7, T9, T11, T13, and T15;   adenocarcinoma: T2, T4, T6, T8, T10, T12, T14 , and T16) were used to detect CCDC85B protein levels. Before tumor excision, all the patients had not received chemotherapy or radiotherapy.
| Immunohistochemistry
Tissue samples were fixed in 4% formalin, embedded in paraffin, and cut into 4-µm sections. Immunohistochemical staining was performed with the streptavidin-peroxidase method using a diaminobenzidene kit (MaiXin, Shenzhen, China). Then the slides were incubated the primary antibody CCDC85B (1:100, Sigma, St. Louis, MO; HPA054415) overnight at 4°C. As a negative control, sections were incubated with phosphate-buffered saline (PBS) instead of the primary antibody. 
| Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde for 15 min and incubated with 0.1% Triton X-100 for 15 min, followed by blocking with goat serum for 2 h at room temperature. The cells were incubated with primary antibodies CCDC85B (1:100, Invitrogen, Carlsbad, CA; PA5-26129) and β-catenin (1:100, BD Biosciences, Franklin Lakes, NJ; 610153) overnight at 4°C, followed by secondary antibody for 1 h at room temperature. Nuclei were stained with DAPI and samples were observed using a Laser scanning confocal microscope (Nikon C2, Nikon, Takyo, Japan).
| Cell culture and transfection
The Lipofectamine 3000 transfection reagent (Invitrogen) was used for cell transfections. After transfection, cells were incubated for 48 h and analyzed using Western blot.
| Western blot
All the proteins from cells were extracted using lysis buffer and 
| Statistical analysis
The software SPSS version 20 was used for all date analyses. The
Chi-square test was used to assess the correlations between CCDC85B expression and clinicopathological factors. Student's t-test was used to compare other data. P < 0.05 was considered statistically significant. GraphPad Prism 5 (GraphPad Software, San Diego, CA) was used for graphs. (Table 1) .
Next, we performed WB analysis in 16 cases of NSCLC tissues and the adjacent non-tumorous lung tissues. The results showed that the level of CCDC85B protein in the NSCLC tissues was significantly higher compared to adjacent non-tumorous lung tissues (0.3438 ± 0.1788 vs 0.1451 ± 0.0898; P < 0.001) ( Figure 1E ). 57.67 ± 8.97 vs 116.00 ± 13.61; P < 0.05) ( Figure 2C ). Conversely, CCDC85B knockdown decreased the proliferation of A549 and H1299 cells ( Figures 2D2 and D4 ), foci number (A549:113.33 ± 10.14 vs 63.33 ± 6.17; P < 0.05; H1299: 108.67 ± 7.13 vs 49.67 ± 5.21; P < 0.01) ( Figure 2E ). CCDC85B ablation reduced the cell invasiveness (A549:98.67 ± 11.86 vs 52.67 ± 6.69; P < 0.05; H1299: 63.00 ± 7.00 vs 38.33 ± 4.06; P < 0.05) ( Figure 2F ).
| CCDC85B overexpression upregulates active β-catenin and wnt targets c-myc, cyclin D1, and MMP7
Reportedly, CCDC85B suppressed the Wnt signaling pathway by inhibiting the interaction of β-catenin with T-cell factor 4 in the nucleus. 11 To elucidate the mechanisms underlying CCDC85B-induced proliferation and invasion of lung cancer cells, we investigated the Wnt signaling pathway. Activation of the Wnt pathway was evaluated by using WB to compare the protein levels of total β-catenin, phosphorylated β-catenin (Ser33/37/Thr41) and actived β-catenin (non-phosphorylated β-catenin, Ser33/37/Thr41). The phosphorylated β-catenin targets β-catenin for ubiquitylation and proteasomal degradation, while actived β-catenin accumulates and translocates to the nucleus, and then activates the Wnt signal pathway combined with TCF/LEF transcription factors. 13 In the current study, we found that CCDC85B overexpression downregulated the phosphorylated β-catenin, and upregulated the active β-catenin and Wnt targets c-myc, cyclin D1, and MMP-7 in A549 and H1299 cells. Accordingly, immunofluorescence assays confirmed that CCDC85B overexpression upregulated nuclear β-catenin. Conversely, CCDC85B ablation upregulated the phosphorylated β-catenin, and downregulated the active β-catenin, Wnt targets c-myc, cyclin D1, and MMP-7 (Figure 3 ).
| CCDC85B regulates Wnt/β-catenin through activation of PI3 K/AKT/GSK3β signaling pathway
GSK3β inhibits Wnt/β-catenin pathway by mediating N-terminal serine-threonine phosphorylation of β-catenin and, thereby, promotes degradation of β-catenin. 14 While Akt phosphorylates GSK3β at Ser 9
and suppresses its activity, and then activated Wnt/β-catenin signaling pathway. 15 To further explore the potential mechanism underlying CCDC85B in the regulation of Wnt/β-catenin, we evaluated the PI3 K/AKT/GSK3β signaling pathway. As shown in Figure 4A and B, Figure 4C) . Furthermore, the CCDC85B plasmid and siRNA-β-catenin were co-transfected into A549 and H1299 cells, the expression levels of β-catenin, phosphorylated β-catenin, active β-catenin were downregulated, and Wnt targets c-myc, cyclin D1, MMP-7 were no longer increased ( Figure 4D ).
| DISCUSSION
Accumulating experimental evidence has indicated that CCDC family members have a pivotal role in several processes associated with tumorigenesis and tumor progression. [3] [4] [5] [6] Nonetheless, the expression patterns and functions of CCDC85B in malignancies remain unknown. To the best of our knowledge, this is the first study that investigated the protein expression of CCDC85B and its correlation with the clinicopathological profiles in NSCLC. Immunohistochemistry and WB methods showed that the level of CCDC85B protein in the NSCLC tissues was significantly higher compared to normal lung tissues, and WB showed that CCDC85B in the lung cancer cell lines was higher compared to HBE cell line. Furthermore, our results demonstrated that the positive expression of CCDC85B correlated with advanced TNM stage and lymph node metastasis.
These data indicated that increased CCDC85B expression was associated with the progression of NSCLS.
Furthermore, we utilized the CCDC85B plasmid and siRNA to examine its physiological role in A549 and H1299 lung cancer cell lines.
MTT and colony formation assays demonstrated that CCDC85B overexpression promoted lung cancer cell proliferation in vitro; also, matrigel invasion assay showed that CCDC85B increased lung cancer cell invasiveness. On the other hand, depletion of endogenous CCDC85B exhibited opposite effects. These data further support the theory that enhanced CCDC85B expression is involved in the malignant progression of lung cancer cells.
CCDC85B has been found within the nucleus and centrosome. [9] [10] [11] Nevertheless, CCDC85B localizes at the adherens junctions in a p120-catenin isoform 1-dependent manner. 16 Moreover, ANKRD26 can alter the CCDC85B localization from the nucleus to cytoplasm in 3T3-L1 cells. 8 Herein, we explored the localization of CCDC85B in NSCLC tissues and lung cancer cells. Immunohistochemistry showed that CCDC85B was located in the cytoplasm of NSCLC tissues, while no CCDC85B was found in the nucleus. This phenomenon was further confirmed by the immunofluorescence, wherein CCDC85B was found to be localized in the cytoplasm in A549 and H1299 lung cancer cells.
The different subcellular localizations of CCDC85B might be attributed to the different cell types or tumor origins.
Reportedly, CCDC85B suppresses the β-catenin activity via interaction with the T-cell factor 4 in the nucleus in a p53-dependent manner.
11
Accordingly, we were curious about the effect of the cytosolic CCDC85B
on Wnt/β-catenin signaling pathway in lung cancer cells. Inconsistent with the above results, we found that cytosolic CCDC85B could activate the Wnt/β-catenin signaling pathway: CCDC85B overexpression could Interestingly, the activation of the Wnt/β-catenin signaling pathway via the cytosolic CCDC85B still needs to be elucidated. It has been reported that AKT phosphorylates GSK3β at Ser9, which leads to β-catenin accumulation and translocation to the nuclear, and then to activation of Wnt signaling pathway. [13] [14] [15] Herein, we observed that CCDC85B overexpression upregulated the levels of phosphorylated AKT and phosphorylated GSK3β, while CCDC85B
knockdown downregulated the levels of phosphorylated AKT and phosphorylated GSK3β. Furthermore, the PI3 K inhibitor, LY294002, rescued the CCDC85B-induced upregulation of phosphorylated GSK3β and active β-catenin. Together, these results demonstrated that cytosolic CCDC85B upregulated the Wnt targets through activated AKT/GSK3β/β-catenin signaling pathway in lung cancer cells.
FIGURE 3 CCDC85B upregulated active β-catenin, Wnt targets c-myc, cyclin D1, and MMP-7. WB analysis showed that CCDC85B overexpression downregulated the phosphorylated β-catenin and upregulated the phosphorylated GSK3β, active β-catenin, and its downstream factors: c-myc, cyclin D1, and MMP-7 in A549 and H1299 cells (A). CCDC85B knockdown displayed opposite effects (B).
Immunofluorescence assays showed that CCDC85B overexpression upregulated the nuclear β-catenin in A549 and H1299 cells (C, D)
In conclusion, we demonstrated that CCDC85B was highly expressed and localized in the cytoplasm of NSCLC tissues and lung cancer cells. CCDC85B overexpression was correlated with advanced TNM stage and lymph node metastasis in NSCLC. CCDC85B
promoted the proliferation and invasion of lung cancer cells by activated AKT/GSK3β/β-catenin oncogenic signaling pathway. These results suggested CCDC85B as a novel target for NSCLC treatment.
